Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Integrated Quality by Design (QbD) Approach for Stability Indicating RPHPLC Method for the Estimation of Tadalafil Hydrochloride in Bulk Drug and Pharmaceutical Formulations

Author(s): Prajakta H. Patil*, Bannimath Gurupadayya and Poornima Hamrapurkar

Volume 17, Issue 7, 2021

Published on: 05 August, 2020

Page: [932 - 944] Pages: 13

DOI: 10.2174/1573412916999200805121131

Abstract

Background: In view of the current FDA standardization and product quality control criteria, Quality by design approach for analytical methods is gaining importance to develop a robust analytical method. A new Quality by Design approach by RP-HPLC was developed and validated for the quantification and purification of Tadalafil hydrochloride and its tablet formulations.

Objective: The objective of the study was to develop and validate a simple, robust, and accurate method by QbD approach for the detection of Tadalafil hydrochloride and its degradation products in bulk drug and tablet formulation.

Methods: The chromatographic separation was performed on JASCO Crest Pack RPC18 column (250mm×4.6mm, 5μm) with mobile phase A consisting of a mixture of Acetonitrile: Methanol (40:20 v/v); and mobile phase B: 0.01M Ammonium acetate in water pH adjusted to 3.50± 0.05 with glacial acetic acid with 1.0ml/min flow rate at 285nm. Box-Behnken's three-level, 3-factorial design was employed to create and analyze a "Design Space" (DoE). This design was statistically analyzed by ANOVA, counter-plot, and 3D response surfaces plots, which demonstrated that the model was statistically significant. The developed method was validated as per the ICH guidelines Q2 (R1).

Results and Discussion: The tadalafil hydrochloride showed good regression (R2>0.9995) within tested ranges, and the percent recovery was found to be 98% in the marketed formulation.

Conclusion: The method was found to be highly specific without the interference of impurities and degradation products of tadalafil hydrochloride. For quantification and routine quality control of tadalafil and its marketed formulation, the stability-indicating the RP-HPLC method could, thus, be extended.

Keywords: Design of Experiments (DoE), forced degradation, formulation, ICH Guidelines, RP-HPLC, Stability Indicating Method Tadalafil hydrochloride.

« Previous Next »
Graphical Abstract

[1]
Ulloa, J.; Sambrotta, L.; Redko, F.; Mazza, O.N.; Garrido, G.; Becher, E.F.; Muschietti, L. Detection of a tadalafil analogue as an adulterant in a dietary supplement for erectile dysfunction. J. Sex. Med., 2015, 12(1), 152-157.
[http://dx.doi.org/10.1111/jsm.12759] [PMID: 25402198]
[2]
Gao, W.; Zhang, Z.; Li, Z.; Liang, G. Chiral separation of two pairs of enantiomers of tadalafil by high-performance liquid chromatography. J. Chromatogr. Sci., 2007, 45(8), 540-543.
[http://dx.doi.org/10.1093/chromsci/45.8.540] [PMID: 18019566]
[3]
Yang, Y.J.; Song, D.M.; Jiang, W.M.; Xiang, B.R. Rapid Resolution RP-HPLC-DAD Method for Simultaneous Determination of Sildenafil, Vardenafil, and Tadalafil in Pharmaceutical Preparations and Counterfeit Drugs. Anal. Lett., 2010, 43(3), 373-380.
[http://dx.doi.org/10.1080/00032710903402283]
[4]
Nikolaou, P.; Papoutsis, I.; Athanaselis, S.; Alevisopoulos, G.; Khraiwesh, A.; Pistos, C.; Spiliopoulou, C. Development and validation of a GC/MS method for the determination of tadalafil in whole blood. J. Pharm. Biomed. Anal., 2011, 56(3), 577-581.
[http://dx.doi.org/10.1016/j.jpba.2011.05.036] [PMID: 21719226]
[5]
Bojanapu, A.; Subramaniam, A.T.; Munusamy, J.; Dhanapal, K.; Chennakesavalu, J.; Sellappan, M.; Jayaprakash, V. Validation and method development of Tadalafil in bulk and tablet dosage form by RP-HPLC. Drug Res. (Stuttg.), 2015, 65(2), 82-85.
[PMID: 24782284]
[6]
Frey, M.K.; Lang, I. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother., 2012, 13(5), 747-755.
[http://dx.doi.org/10.1517/14656566.2012.662220] [PMID: 22356534]
[7]
Vredenbregt, M.J.; Blok-Tip, L.; Hoogerbrugge, R.; Barends, D.M.; de Kaste, D. Screening suspected counterfeit Viagra and imitations of Viagra with near-infrared spectroscopy. J. Pharm. Biomed. Anal., 2006, 40(4), 840-849.
[http://dx.doi.org/10.1016/j.jpba.2005.07.048] [PMID: 16229983]
[8]
Rao, D.V.S.; Radhakrishnanand, P.; Himabindu, V. Stress Degradation Studies on Tadalafil and Development of a Validated Stability-Indicating LC Assay for Bulk Drug and Pharmaceutical Dosage Form. Chromatographia, 2008, 67(1–2), 183-188.
[http://dx.doi.org/10.1365/s10337-007-0478-1]
[9]
Gratz, S.R.; Flurer, C.L.; Wolnik, K.A. Analysis of undeclared synthetic phosphodiesterase-5 inhibitors in dietary supplements and herbal matrices by LC-ESI-MS and LC-UV. J. Pharm. Biomed. Anal., 2004, 36(3), 525-533.
[http://dx.doi.org/10.1016/j.jpba.2004.07.004] [PMID: 15522526]
[10]
Ramakrishna, N.V.S.; Vishwottam, K.N.; Puran, S.; Koteshwara, M.; Manoj, S.; Santosh, M.; Chidambara, J.; Wishu, S.; Sumatha, B. Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 809(2), 243-249.
[http://dx.doi.org/10.1016/S1570-0232(04)00515-X] [PMID: 15315772]
[11]
Ali, I.; Aboul-Enein, H.Y. Validated Method for Tadalafil Analysis in Pharmaceutical Preparations by Capillary Electrophoresis. Chromatographia, 2004, 60(3–4), 187-191.
[http://dx.doi.org/10.1365/s10337-004-0366-x]
[12]
Farthing, C.A.; Farthing, D.E.; Koka, S.; Larus, T.; Fakhry, I.; Xi, L.; Kukreja, R.C.; Sica, D.; Gehr, T.W.B. A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2010, 878(28), 2891-2895.
[http://dx.doi.org/10.1016/j.jchromb.2010.07.022] [PMID: 20801090]
[13]
Patel, J.K.; Patel, N.K. Stability-Indicating RP-HPLC Method for the Determination of Ambrisentan and Tadalafil in Pharmaceutical Dosage Form. Sci. Pharm., 2014, 82(4), 749-763.
[http://dx.doi.org/10.3797/scipharm.1403-22] [PMID: 26279975]
[14]
Reddy, B.P.; Reddy, K.A.; Reddy, M.S. Validation and Stability Indicating RP-HPLC Method,2010. Pdf., 2010, 2(1), 1-6.
[15]
Fukuda, I.M.; Pinto, C.F.F.; Moreira, C.D.S.; Saviano, A.M.; Lourenço, F.R. Design of Experiments (DoE) Applied to Pharmaceutical and Analytical Quality by Design (QbD). Braz. J. Pharm. Sci., 2018, 54(Special Issue), 1-16.
[http://dx.doi.org/10.1590/s2175-97902018000001006]
[16]
Bhutani, H.; Kurmi, M.; Singh, S.; Beg, S.; Singh, B. Quality by Design (QbD) in Analytical Sciences: An Overview. Pharm. Times, 2014, 46(8), 71-75.
[17]
Sultana, S.; Kumar, U.; Hossain, M.S.; Lira, D.N.; Rouf, A.S.S. QbD Approach for the Development and Validation of RP-UHPLC Method for Quantitation of Vildagliptin. Dhaka Univ. J. Pharm. Sci., 2017, 16(1), 107-117.
[http://dx.doi.org/10.3329/dujps.v16i1.33388]
[18]
Demire, G.; Saray, D.; Yaman, B.Y.A.T.; Turkyilmaz, A. Quality by Design Approach for an Orally Disintegrating Tablet Analytical Method Validation. Int. J. Pharm. Sci. Drug Res., 2018, 10(01), 12-19.
[http://dx.doi.org/10.25004/IJPSDR.2018.100103]
[19]
Agency, E.M. European Medicines Agency: an unacceptable choice. Prescrire Int., 2011, 20(121), 278.
[PMID: 22066320]
[20]
Karmarkar, S.; Garber, R.; Genchanok, Y.; George, S.; Yang, X.; Hammond, R.; Corporation, B.H.; Park, T.; Route, W.I.L.; Lake, R. Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities. J. Chromatogr. Sci., 2011, 49(6), 439-446.
[http://dx.doi.org/10.1093/chrsci/49.6.439] [PMID: 21682993]
[21]
Kumar, L.; Vajrala, G. Quality by design: design of experiments approach prior to the validation of a stability-indicating hplc method for montelukast. Chromatographia, 2013, 76, 1697-1706.

Rights & Permissions Print Cite
Article Metrics
10
1
© 2024 Bentham Science Publishers | Privacy Policy